YU32702A - Nepeptidni supstituisani benzotiazepini kao antagonisti vazopresina - Google Patents

Nepeptidni supstituisani benzotiazepini kao antagonisti vazopresina

Info

Publication number
YU32702A
YU32702A YU32702A YUP32702A YU32702A YU 32702 A YU32702 A YU 32702A YU 32702 A YU32702 A YU 32702A YU P32702 A YUP32702 A YU P32702A YU 32702 A YU32702 A YU 32702A
Authority
YU
Yugoslavia
Prior art keywords
formula
ischemia
treating conditions
vasopressin antagonists
nonpeptide substituted
Prior art date
Application number
YU32702A
Other languages
English (en)
Inventor
Maud Urbanski
Robert H.K. Chen
Original Assignee
Ortho-Mcneil Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical Inc. filed Critical Ortho-Mcneil Pharmaceutical Inc.
Publication of YU32702A publication Critical patent/YU32702A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Pronalazak se odnosi na nepeptidne supstituisane benzodiazepine formule (I), gde A, X, Z, Bp, W, n, R1 i R2 su opisani u prijavi, koji su korisni kao antagonisti vazopresin receptora za lečenje stanja koja povećavaju vaskularnu rezistenciju i srčanu insuficijenciju. Takodje su otkrivene farmaceutske kompozicije koje obuhvataju jedinjenja formule (I) i postupci lečenja stanja kao što je hipertenzija, kongestivni zastoj srca, srčana insuficijencija, koronarni vazospazam, srčana ishemija, ciroza jetre, renalni vazospazam, renalni zastoj, cerebralni edem i ishemija, udar, tromboza ili zadržavanje vode.[The invention is directed to nonpeptide substituted benzodiazepines of Formula (I), wherein A, X, Z, Bp, W, n, R1 and R2 are as described in the specification, which are useful as vasopressin receptor antagonists for treating conditions involving increased vascular resistance and cardiac insufficiency. Pharmaceutical compositions comprising a compound of Formula (I) and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention are also disclosed.
YU32702A 1999-11-04 2000-11-02 Nepeptidni supstituisani benzotiazepini kao antagonisti vazopresina YU32702A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16354499P 1999-11-04 1999-11-04

Publications (1)

Publication Number Publication Date
YU32702A true YU32702A (sh) 2005-06-10

Family

ID=22590503

Family Applications (1)

Application Number Title Priority Date Filing Date
YU32702A YU32702A (sh) 1999-11-04 2000-11-02 Nepeptidni supstituisani benzotiazepini kao antagonisti vazopresina

Country Status (17)

Country Link
US (1) US6489321B1 (sh)
EP (1) EP1226132A1 (sh)
JP (1) JP2003513082A (sh)
KR (1) KR20020047321A (sh)
CN (1) CN1414958A (sh)
AR (1) AR026360A1 (sh)
AU (1) AU778810B2 (sh)
BR (1) BR0015299A (sh)
CA (1) CA2389439A1 (sh)
CZ (1) CZ20021492A3 (sh)
HU (1) HUP0204278A2 (sh)
MX (1) MXPA02004513A (sh)
PL (1) PL354759A1 (sh)
RU (1) RU2002111660A (sh)
SK (1) SK6052002A3 (sh)
WO (1) WO2001032639A1 (sh)
YU (1) YU32702A (sh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
JP3988832B2 (ja) * 2004-11-29 2007-10-10 日本たばこ産業株式会社 窒素含有縮合環化合物及びその用途
JO3109B1 (ar) * 2012-05-10 2017-09-20 Ferring Bv منبهات لمستقبلات v1a

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2751287B2 (ja) * 1989-01-09 1998-05-18 吉富製薬株式会社 １，５‐ベンゾチアゼピン‐２‐カルボン酸アミド化合物
EP0450097B1 (en) 1989-10-20 1996-04-24 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
TW199153B (sh) 1990-08-07 1993-02-01 Dtsuka Seiyaku Kk
JPH05320135A (ja) 1992-05-19 1993-12-03 Yamanouchi Pharmaceut Co Ltd テトラヒドロベンズアゼピン誘導体
JPH0680641A (ja) 1992-09-01 1994-03-22 Otsuka Pharmaceut Co Ltd 光学活性な５−ヒドロキシベンゾアゼピン誘導体の製造法
SK94393A3 (en) 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
DE69430861T2 (de) 1993-04-07 2003-01-23 Otsuka Pharmaceutical Co., Ltd. N-acylierte 4-aminopiperidin derivate als aktive bestandteile von peripher gefässerweiternden wikstoffen
MX9709874A (es) 1995-06-06 1998-03-31 Pfizer N-(INDOL-2-CARBONIL) beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO INHIBIDORES DE GLUCOGENO FOSFORILASA, USO DE LOS MISMOS Y COMPOSICIONES QUE LOS CONTIENEN.
DE69523182T2 (de) 1995-06-06 2002-02-07 Pfizer Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren
EP0939632B1 (en) 1996-02-23 2005-10-05 Eli Lilly And Company NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS
JP3483893B2 (ja) 1996-09-10 2004-01-06 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング 修飾アミノ酸、これらの化合物を含む薬物及びそれらの調製方法
US5952322A (en) 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
US6063796A (en) 1997-04-04 2000-05-16 Merck & Co., Inc. Somatostatin agonists
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
DE19748763A1 (de) 1997-11-05 1999-05-06 Hans Peter Zenner Verwendung von Vasopressin-Antagonisten
AUPP150098A0 (en) 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
DK1086086T3 (da) 1998-06-12 2005-01-24 Sod Conseils Rech Applic Imidazolylderivater og anvendelse deraf som somatostatinreceptorligander
CA2345357A1 (en) 1998-09-30 2000-04-06 Merck Sharp & Dohme Limited Benzimidazolinyl piperidines as cgrp ligands
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
US6297234B1 (en) 1999-02-04 2001-10-02 American Home Products Corporation Arylthiophene vasopressin agonists

Also Published As

Publication number Publication date
CA2389439A1 (en) 2001-05-10
MXPA02004513A (es) 2004-09-10
AR026360A1 (es) 2003-02-05
US6489321B1 (en) 2002-12-03
CN1414958A (zh) 2003-04-30
PL354759A1 (en) 2004-02-23
KR20020047321A (ko) 2002-06-21
WO2001032639A1 (en) 2001-05-10
SK6052002A3 (en) 2003-09-11
AU1754001A (en) 2001-05-14
EP1226132A1 (en) 2002-07-31
CZ20021492A3 (cs) 2003-06-18
HUP0204278A2 (hu) 2003-04-28
RU2002111660A (ru) 2003-11-27
AU778810B2 (en) 2004-12-23
JP2003513082A (ja) 2003-04-08
BR0015299A (pt) 2003-04-15

Similar Documents

Publication Publication Date Title
WO2000043398A3 (en) Tricyclic benzodiazepines as vasopressin receptor antagonists
TWI316057B (en) Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
SI2078022T1 (sl) Spiro benzazepini, uporabljeni kot antagonisti vazopresina
NO20060247L (no) Substituerte spirobenzazepiner
MXPA02004513A (es) Benzotiazefinas sustituidas no peptidicas como antagonistas de vasopresina.
WO2006049984A3 (en) Novel [1,4]benzodiazepines as vasopressin v2 receptor antagonists
IL147130A0 (en) Indoloazepines as vasopressin receptor antagonists
HU9402429D0 (en) Pyrazolopyrimidin derivatives as angiotensin ii receptor antagonists